Usefulness of initial plasma dabigatran concentration to predict rebound after reversal

Haematologica. 2018 May;103(5):e226-e229. doi: 10.3324/haematol.2017.183400. Epub 2018 Feb 22.

Authors

Nicolas Gendron^{1

2

3}, Juliette Gay^{1

2}, Marine Lemoine⁴, Pascale Gaussem^{1

2

3}, Agnès Lillo-Le-Louet⁴, David M Smadja^{5

2

3}

Affiliations

¹ AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France.
² Université Paris Descartes, Sorbonne Paris Cite, Paris, France.
³ Inserm UMR-S1140, Paris, France.
⁴ AP-HP, European Hospital Georges Pompidou, Regional Center of Pharmacovigilance, Paris, France.
⁵ AP-HP, European Hospital Georges Pompidou, Hematology Department, Paris, France david.smadja@aphp.fr.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / administration & dosage*
Antithrombins / administration & dosage
Antithrombins / adverse effects*
Antithrombins / blood
Dabigatran / administration & dosage
Dabigatran / adverse effects*
Dabigatran / blood
Female
Hemorrhage / blood*
Hemorrhage / chemically induced
Hemorrhage / drug therapy*
Humans
Male
Middle Aged
Prognosis
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Antithrombins
idarucizumab
Dabigatran